Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone hemisuccinate
Drug ID BADD_D01435
Description A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB14644
KEGG ID D05000
MeSH ID D008776
PubChem ID 16923
TTD Drug ID Not Available
NDC Product Code 57582-012; 24002-0015; 82298-109; 22552-0024; 52128-152
Synonyms Methylprednisolone Hemisuccinate | Hemisuccinate, Methylprednisolone | Methylprednisolone Succinate | Succinate, Methylprednisolone | Urbason-Soluble | UrbasonSoluble | Solu-Medrol | Solumedrol | A-MethaPred | Methylprednisolone Sodium Succinate | Sodium Succinate, Methylprednisolone | Methylprednisolone Hemisuccinate Monosodium Salt | 6 alpha-Methylprednisolone Sodium Hemisuccinate | Methylprednisolone Sodium Hemisuccinate | Sodium Hemisuccinate, Methylprednisolone
Chemical Information
Molecular Formula C26H34O8
CAS Registry Number 2921-57-5
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Treatment failure08.06.01.0170.010948%Not Available
Liver injury12.01.02.003; 09.01.07.0220.014597%Not Available
Epidural lipomatosis17.10.01.012; 14.08.04.019--Not Available
Oropharyngeal pain07.05.05.004; 22.02.05.022--
Acute kidney injury20.01.03.016--
Bladder dysfunction20.03.03.002--Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.090929%
Functional gastrointestinal disorder07.11.01.016--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.118908%Not Available
Substance-induced psychotic disorder12.03.01.053; 19.03.01.0070.027978%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.007299%Not Available
Candida infection11.03.03.0210.020984%
Aspergillus infection11.03.01.0040.003649%Not Available
Language disorder17.02.08.015; 19.19.01.0060.020984%Not Available
Varicella zoster virus infection11.05.02.0230.003649%Not Available
Perforation08.01.03.0580.013989%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Blood pressure immeasurable13.14.03.0260.005474%Not Available
Cellulitis orbital11.02.01.035; 06.04.11.0010.013989%Not Available
Persecutory delusion19.10.01.0070.013989%Not Available
Pulmonary mycosis22.07.08.013; 11.03.05.0270.020984%Not Available
Thyrotoxic periodic paralysis17.01.04.021; 14.11.01.045; 05.02.02.0050.013989%Not Available
Viral myocarditis02.04.04.001; 11.05.04.0300.013989%Not Available
Cardiomyopathy acute02.04.01.0080.003649%Not Available
Pulmonary sepsis22.07.01.014; 11.01.11.0140.013989%Not Available
Stenotrophomonas infection11.02.01.0490.003649%Not Available
Cell death14.11.02.005; 08.03.03.0030.020984%Not Available
Secondary progressive multiple sclerosis17.16.01.0080.013989%Not Available
Rectal fissure07.03.01.0070.013989%
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages